AbbVie
7 articles on AbbVie, researched and written by the Shotlee Editorial Team from primary sources.
Kailera Therapeutics Eyes IPO for Obesity Drug Pipeline
Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.
5 min read
Ireland's Each-Way Bet on Wegovy and Mounjaro Rivals
A spectacular backfire in Novo Nordisk's head-to-head trial against Eli Lilly's Mounjaro has widened the gap in the weight loss drug race, yet Ireland stands to gain from both giants. With billions in investments, thousands of jobs, and massive tax revenues, the Republic is placing an each-way bet on Wegovy and Mounjaro. This economic tie underscores pharma's pivotal role in Ireland's prosperity.
6 min read
AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments
AbbVie is bolstering its obesity portfolio with GUBamy, an amylin-based drug from Gubra as a GLP-1 alternative. Unlike gut hormone-mimicking GLP-1s like Wegovy and Zepbound, amylin targets pancreatic hormones for improved tolerability and muscle retention. The company eyes long-term efficacy amid a $150B market boom.
1 min read
FDA Approvals for 2025
In 2025, the FDA approved 46 novel therapeutic agents from its Center for Drug Evaluation and Research, marking a slight dip from the five-year average but remaining above historical norms. Cancer led approvals, with advancements in modalities like kinase inhibitors and gene therapies. The year also introduced new programs and faced staffing challenges under changing leadership.
13 min read
Oral Proteins & Peptides Market to Reach USD 47.2 Billion Globally by 2035, Exhibiting 15.3% CAGR - TMR Study
The global market for oral proteins and peptides is experiencing rapid expansion, with projections estimating a value of US$ 47.2 billion by 2035. This growth, driven by increasing demand for peptide-based therapeutics and advancements in delivery technologies, signifies a dynamic shift in the pharmaceutical and nutraceutical landscape.
6 min read
Lilly's Eloralintide Obesity Drug Advances to Phase 3 Trials
Eli Lilly is progressing its experimental amylin obesity drug, eloralintide, into late-stage clinical trials following successful phase 2 study outcomes. The mid-stage study demonstrated significant weight loss in participants receiving the highest dose of the drug.
3 min read
Eli Lilly Advances Amylin Obesity Drug to Late-Stage Trials After Study Shows 20% Weight Reduction
Eli Lilly is set to begin late-stage trials for its investigational amylin obesity drug following promising mid-stage study results. The trial showed the highest dose of the weekly injection, eloralintide, resulted in an average weight loss of 20.1% in obese or overweight patients over 48 weeks.
3 min read